WO1998040103A1 - Procede visant a renforcer l'effet therapeutique et a reduire la toxicite de medicaments, de metaux ainsi que de composes organiques ou inorganiques - Google Patents

Procede visant a renforcer l'effet therapeutique et a reduire la toxicite de medicaments, de metaux ainsi que de composes organiques ou inorganiques Download PDF

Info

Publication number
WO1998040103A1
WO1998040103A1 PCT/RU1997/000261 RU9700261W WO9840103A1 WO 1998040103 A1 WO1998040103 A1 WO 1998040103A1 RU 9700261 W RU9700261 W RU 9700261W WO 9840103 A1 WO9840103 A1 WO 9840103A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
οсη
drugs
disease
toxicity
Prior art date
Application number
PCT/RU1997/000261
Other languages
English (en)
Russian (ru)
Inventor
Vladimir Viktorovich Scherbinin
Evgeny Andreevich Chernyshev
Original Assignee
Kuzmin, Konstantin Kuzmich
Volotovsky, Andrei Vasilievich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU97103219A external-priority patent/RU2104033C1/ru
Priority claimed from RU97103218A external-priority patent/RU2104032C1/ru
Application filed by Kuzmin, Konstantin Kuzmich, Volotovsky, Andrei Vasilievich filed Critical Kuzmin, Konstantin Kuzmich
Priority to AU39552/97A priority Critical patent/AU3955297A/en
Publication of WO1998040103A1 publication Critical patent/WO1998040103A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol

Definitions

  • Iz ⁇ b ⁇ e ⁇ enie ⁇ n ⁇ si ⁇ sya K medicine b ⁇ lee ⁇ chn ⁇ , K ⁇ a ⁇ ma ⁇ l ⁇ gii and m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ ⁇ i ⁇ a ⁇ ma ⁇ e ⁇ a ⁇ ii vse ⁇ vid ⁇ v zab ⁇ levaniya in ⁇ m including ⁇ i dezin ⁇ si ⁇ atsii ⁇ ganizma ⁇ sle ⁇ iema lechebny ⁇ s ⁇ eds ⁇ v, me ⁇ all ⁇ v, ⁇ ganiches ⁇ i ⁇ and ne ⁇ ganiches ⁇ i ⁇ s ⁇ edineny.
  • a handy action can be primary and secondary. Primary activity is directly related to the effect of this drug on a divided substance (for example, it is irrelevant).
  • the beneficial effect may be directed to the neural system, the wrist and the wrist, the wounds, the smoke, the digestion, the kidneys, the endocrine glands and others.
  • ⁇ ⁇ itsa ⁇ elnym influences ⁇ azyvaemym le ⁇ a ⁇ s ⁇ vennymi vesches ⁇ vami, ⁇ n ⁇ sya ⁇ sya ⁇ a ⁇ zhe
  • Idysyncrasia may also be one of the reasons for adverse reactions to substances. Excessive substances that increase therapeutic substances cause toxic effects.
  • Medicinal products may possess mutagenic and embryonic properties. Particularly convenient for simple medical devices, this is a good add-on for easy access to drugs. It is impracticable to consume a substance, usually for the purpose of ⁇ 0 98740103 ⁇ / ⁇ 7 / 00261
  • one of the applied antagonists and antagonists does not have a wide range of actions to reduce the adverse effects of all or many medications.
  • various substances were investigated, including German organic substances.
  • the drugs are used on the basis of all kinds of stimulants (for example, specific antibiotic therapy).
  • stimulants for example, specific antibiotic therapy.
  • the closest to the action to the declared compounds are those that are used in the treatment of immunostimulating drugs.
  • Immunity stimulating (normalizing) immune reactions, are used in the complex therapy of immunodeficiency, chronic infections, and malignant. ⁇ Canal As a part of immunostimulants, they use biogenic substances (thymus preparations, interns, BCG) and synthetic compounds
  • BCG ( ⁇ ) is used for vaccination against tuberculosis. At present, BCG is used in the complex therapy of a series of malignant tumors. BCG stimulates macrophages and, obviously, ⁇ -lymphocytes. A beneficial effect is noted for simple myeloid leukemia, certain types of lymph (non-persistent lymphadenopathy), and intestinal gland.
  • levamisole drug
  • levamisole drug
  • hydrolide hydrolide
  • levamisol exerts a stimulating effect on macros and sammlung jointly-lymphocytes. It does not alter the production of antibodies. Consequently, the main levamisole effect is manifested in normalization of cell-mediated immunization. They use it for immunodeficiency, some chronic infections, a rheumatic disease, and a number of pulses.
  • Levamisole in a combination with specifically active drugs is designated. Leave inside. With its single use, no harmful effects are observed in practice. In addition to the levamisole administration, especially if the doses are large, there are a lot of common things, including the good ones. So, allergic reactions (rash, fever, stool), oppression can be expressed ⁇ ⁇ 98/40103 ⁇ 97 / 00261
  • the source method [1] is taken as a method for the claimed method. DISCLOSURE OF INVENTION.
  • Germanic compounds of formulas I and 2 if administered together with medicinal products, enhance the therapeutic effect of the reduced incidence of medication. ⁇ ⁇ 98/40103
  • ⁇ is a water or organic radical or an element of a radical, including, but not limited to, medicinal products; - ⁇ - ⁇ - a water or urban radical or a military unit;
  • ⁇ - ⁇ 2 is a water or organic radical or an elementary urban radical, including a unique medicinal product; ⁇ 3 - ⁇ - water or urban radical; X - acid or sulfur;
  • the radicals ⁇ and ⁇ 2 may be chemically linked to each other
  • germanic compounds of the general general formula (1 and 2) (HES) is significant U ⁇ 98/40103 ⁇
  • the HSE By blocking the various links in the development of disease, by simultaneously increasing the rate of growth of the organism, the HSE has a curative effect on health.
  • a similar HES enhances the activity of biologically active substances found in food, which are used in food and medical treatment, as well as in medical treatment.
  • the Germanic acid compounds themselves do not have any toxic effects and no adverse effects on the patient. ⁇ ⁇ 98/40103 ⁇ 97 / 00261
  • Fig. 2 shows the progression of the development of AIDS.
  • the GHS enhances the action of all known industrial products of adamant derivatives - mithandane, rimantadine, analogs of nuclides - azidothymidine, azits ⁇ ⁇ 98/40103 ⁇ 97 / 0026 ⁇
  • the scuffling was carried out with a convenient lancet, after which, as live animals were anesthetized, they were anesthetized.
  • the size of the area of scarification was 4–7 mm. Souring liquid was applied using imprints immediately after compression (with the following intrusion).
  • the clinical symptoms of the genital herpes were regis tered daily by treatment and monitored during the course of the disease.
  • the products were sprinkled and the 1H-hydrohydroxyhydrate in the form of films on the main biological products was added to the effect of the animal being consumed and the food was consumed.
  • Treatment was started after 48 hours after infection and the presence of a well-expressed disease.
  • the 1st group contained only infor- mated KPG-2 live animals that were not processed in any way.
  • the 2nd group consisted of lively infused KPG-2 and received 20 mg of phosphate 1 time in a day.
  • the 3rd group consisted of lively infected PG-2 and received 20 mg of phosphate in combination with 1 mg of HS 1 day.
  • the rash in all patients was provided by the use of natural elements on a completely hyperactive condition and was accompanied by itching and burning sensation.
  • the patient was either clinically or hypertensive, had vesicles, had erosion, had erosion,
  • the duration of this phase can be cured in an average of 3 to 8 days.
  • P ⁇ i ⁇ vedenii anal ⁇ gichny ⁇ is ⁇ y ⁇ any with ⁇ iv ⁇ ge ⁇ e ⁇ iches ⁇ im ⁇ e ⁇ a ⁇ a ⁇ m atsi ⁇ l ⁇ vi ⁇ (replacement ⁇ s ⁇ a ⁇ ne ⁇ a on atsi ⁇ l ⁇ vi ⁇ ) were ⁇ lucheny anal ⁇ gichnye ⁇ ezul ⁇ a ⁇ y: znachi ⁇ eln ⁇ e increase lechebn ⁇ g ⁇ deys ⁇ viya atsi ⁇ l ⁇ vi ⁇ a and reducing eg ⁇ ⁇ b ⁇ chny ⁇ e ⁇ e ⁇ v ⁇ i eg ⁇ ⁇ imenenii s ⁇ vmes ⁇ n ⁇ with G ⁇ S. (See table 7)
  • the designation of the GHS in the direct management of a simple and indirect disease has a significant effect on the development and management of the disease. (Food supplement).
  • the severity of the main symptoms (temperature, weakness, cough, headache) was reduced, the rate of illness was reduced, the incidence of the disease was reduced.
  • the disease caused the development of a stable immunodeficiency virus (the observation period is five years).
  • Group disease was not observed. However, it was possible that the group was observed, but its symptoms were significantly weakened and did not differ from ordinary foodstuffs. The incidence of the disease lasted 1-2 days with a small ⁇ ⁇ 98/40103 ⁇ 97 / 00261
  • AIDS treatment AIDS-related infections
  • the treatment of AIDS vaccine The proposed GEOs are practically ideal for the treatment of AIDS, AIDS-related infections in the general public, and AIDS-related diseases.
  • azidothymidine occurs mainly during the first 6–8 months of treatment initiation.
  • Azidothymidine in the main, does not cure the sick, but only delays the development of the disease.
  • the drug is developed to be resistant to the disease. From the usual effects of azidothymidine in the first place, hematologic symptoms are anesthetized: anemia, neutropenia, and blood pressure. Headache, insomnia, myalgia, oppression of the liver function are possible.
  • the body grows smaller, then the immune response develops and the number of viral particles is substantially reduced. Most often, the immune system usually functions normally and keeps the virus clean (good line). But, nevertheless, it is gradually dispersed in the organism and takes a moment, when the bowl is weighed down in the virus and the immune system disappears.
  • GC cyclopentasine
  • the drug treatment for AIDS is changing to a significant extent. Significantly, the efficacy of azidothymidine is increased, and the drug is not stable or develops slowly. The normal effects observed by the usual use of azidothymidine are slightly reduced.
  • the treatment or significant slowdown in the production of cyanide plaques and neurophysiological clubbing is the key to the treatment of the death of a person.
  • the GS is effective and severe for severe diseases of the central and primary non-invasive system. 98/40103 ⁇ 97 / 00261
  • the GHS is a local means of the prevention of all listed neurological diseases:
  • One of the limiting aspects in the treatment of malignant neoplasms is the overheating of pulmonary cells in the form of drugs. It is possible to slow down the process of digesting by known means by combining the use of drugs with a different structure and non-uniform mechanism.
  • HES HES on the basis of a general therapies made it easier to increase the efficiency of the drugs, while having a significant effect on It has been found that there is no danger of getting or slowing down the pockets of chemicals.
  • the GSU while protecting the healthy cells of the body, makes the non-vulnerable public cells safe.
  • a slight decrease in the toxic effects on the body of the economy is more likely to cause a significant increase in the risk of increased labor costs and is more likely to increase the risk of ⁇ ⁇ 98/40103 ⁇ 97 / 00261
  • HEPs are effective when they are physically removed from radiation and radiation therapy. When treating the HCV cancer, it is recommended that you continue to take care of the disease for the second time.
  • GUS was prescribed as a large cancer of the 3-4 stages of the small gland, lumbar gland, direct bones, brown tissue of the chest and other arteries in the surgical process.
  • ⁇ ⁇ aches ⁇ ve ge ⁇ maniy ⁇ ganiches ⁇ i ⁇ ⁇ e ⁇ a ⁇ a ⁇ v used if ⁇ imeneny m ⁇ n ⁇ gid ⁇ i ⁇ 1 gid ⁇ sige ⁇ ma ⁇ ana, dige ⁇ ma ⁇ anil ⁇ sid, di ⁇ i ⁇ ge ⁇ ma ⁇ anil ⁇ sid, 1- ( ⁇ ime ⁇ ilsil ⁇ si) ge ⁇ ma ⁇ an, 1- (n- ⁇ si) ge ⁇ ma ⁇ an, 1- ( ⁇ ie ⁇ ilge ⁇ m ⁇ si) ge ⁇ ma ⁇ an 9 me ⁇ il--1, 4, 6, 12 -tetoxa-9-aza-5-germaside [4,7] dodecane, derivative sarcolysine and 1-hydroxyhexmaphthan (hemethanilic ester of b- ⁇ -amine- ⁇ -p Germanic Urban Compounds (GS).
  • the foodstuffs are used as food additives.
  • hypoxia is a key moment in the development of ischemic heart disease.
  • Specific safe antigens to fight this pathology are not practical.
  • the manifestation of new drugs for the treatment of heart-vessel diseases would be of great practical importance.
  • HES ulcerative colitis
  • Intensity and duration of pain decreased, arrhythmia, general well-being improved, gradual recovery was restored, even in extreme cases.
  • HES is effective for preventing infections and external fatalities, as well as in postinfective therapy.
  • the susceptibility has improved and the negative impact on the body of the traditional treatment has decreased.
  • Anticoagulants heparin and others
  • Germanic compounds with painkillers and analgesics P ⁇ i ⁇ imenenii G ⁇ S: m ⁇ n ⁇ gid ⁇ a ⁇ a 1 gid ⁇ sige ⁇ ma ⁇ ana, dige ⁇ ma ⁇ anil ⁇ sida, 1- ( ⁇ ie ⁇ ilge ⁇ m ⁇ si) ge ⁇ ma ⁇ ana with analge ⁇ i ⁇ ami and ⁇ iv ⁇ v ⁇ s ⁇ ali ⁇ elnymi ⁇ e ⁇ a ⁇ a ⁇ ami - atse ⁇ ilsalitsil ⁇ vaya ⁇ isl ⁇ a, ⁇ a ⁇ atse ⁇ am ⁇ l, amid ⁇ i ⁇ in, analgin, bu ⁇ adi ⁇ n, ind ⁇ me ⁇ atsin and d ⁇ .
  • Germanic compounds in conjunction with tranquilizations.
  • the efficacy of the use of pressure stabilizers was increased to reduce insomnia, to suppress feelings of stress, anxiety, agitation, tension.
  • Increased i ⁇ e ⁇ e ⁇ ivn ⁇ s ⁇ ⁇ i treatment ⁇ azlichny ⁇ ⁇ si ⁇ iches ⁇ i ⁇ zab ⁇ levany and ⁇ g ⁇ anichny ⁇ s ⁇ s ⁇ yany, na ⁇ ime ⁇ , shiz ⁇ enii with nev ⁇ z ⁇ d ⁇ bn ⁇ y sim ⁇ ma ⁇ i ⁇ y, de ⁇ essivny ⁇ and i ⁇ nd ⁇ iches ⁇ i ⁇ s ⁇ s ⁇ yaniya ⁇ for ⁇ u ⁇ i ⁇ vaniya Sind ⁇ ma abs ⁇ inentsii ⁇ i al ⁇ g ⁇ lizme and d ⁇ ugi ⁇ zab ⁇ levaniya ⁇ .
  • the HGS is well compatible with dental component parts that protect against tooth decay, which incorporates a compound connection, and significantly enhances its effect. In general, it was possible to create a practically perfect dental stock.
  • Granular acne is one of the most common destructive diseases in young people and young people. ⁇ ul ⁇ i ⁇ a ⁇ ialnaya ⁇ i ⁇ da zab ⁇ levaniya, availability ⁇ sme ⁇ iches ⁇ i ⁇ de ⁇ e ⁇ v on ⁇ zhe person g ⁇ udi and s ⁇ iny, ⁇ niches ⁇ i- ⁇ etsidivi ⁇ uyuschie ⁇ echenie ⁇ a ⁇ l ⁇ giches ⁇ g ⁇ ⁇ tsessa and ⁇ a ⁇ zhe ⁇ idn ⁇ s ⁇ ⁇ ⁇ v ⁇ dim ⁇ y ⁇ e ⁇ a ⁇ ii in b ⁇ lshins ⁇ va b ⁇ lny ⁇ ⁇ buslavlivayu ⁇ ⁇ sn ⁇ vnuyu ⁇ ichinu ⁇ su ⁇ s ⁇ viya nadezhny ⁇ me ⁇ d ⁇ v treatment e ⁇ g ⁇ zab ⁇ levaniya. Therefore, the search for and use of new medicinal products and forms remains an urgent task for dealers
  • the curative effects of the drug are controlled by the main methods of the treatment of sucessodism, one and the same efficacy. ⁇ ⁇ 98/40103 ⁇ 97 / 0026 ⁇
  • Lossien “SED” recommended that you apply (with the help of spray) to the affected areas 2 times a day (morning and evening) after the face of the person for 10-14 days.
  • Patient and symptomatic treatment of patients was not prescribed for the purpose of receiving the available data on the efficacy of treatment with lacquer "SED". Each patient was observed for 2 weeks.
  • the complex product is a highly effective medication for the treatment of vulgar acne and is effective in treating it. For this reason, the use of the GES has improved the therapeutic effect of the treatment of the disease.
  • ⁇ a ⁇ im ⁇ b ⁇ az ⁇ m ⁇ imenenie G ⁇ S ⁇ zv ⁇ lyae ⁇ znachi ⁇ eln ⁇ ⁇ vysi ⁇ inde ⁇ s lechebn ⁇ g ⁇ deys ⁇ viya izves ⁇ ny ⁇ ⁇ e ⁇ a ⁇ a ⁇ v ⁇ i ⁇ yazhely ⁇ zab ⁇ levaniya ⁇ : AIDS, ⁇ unis ⁇ iches ⁇ ie in ⁇ e ⁇ tsii ⁇ i AIDS nev ⁇ l ⁇ giches ⁇ ie ⁇ azheniya tsen ⁇ aln ⁇ y and ne ⁇ vn ⁇ y sis ⁇ emy, ⁇ n ⁇ l ⁇ giches ⁇ ie zab ⁇ levaniya, ishemiches ⁇ aya b ⁇ lezn se ⁇ dtsa and d ⁇ and ⁇ a ⁇ zhe ⁇ s ⁇ udny ⁇ zab ⁇ levany, ge ⁇ e ⁇ iches ⁇ i ⁇ in ⁇ e ⁇ t
  • HIV positive * was studied in 23 patients with peptic ulcer disease (7 men and 16 women) aged 21 to 62 years. The duration of the disease was relieved from 2 to 14 years. In all patients at the time of the study, peptic ulcer disease was present in the stage of the expressed clinical disease. Before using the gastrointestinal department, the patients did not accept any type of treatment. * 1-hydroxyhydroxyhydroxyhydroxyhydroxyhydroxyhydramate, dihydrohydroxyloid acid, 1- (triethylhydroxy) hydrohormate.
  • the on-site group consisted of 30 patients with ulcerous disease, which are comparable to patients with an experienced group, ⁇ ⁇ 98/40103 ⁇ 97 / 00261
  • the pain syndrome was cured in patients who had a GHS with an average of 7.5 ⁇ 0.8 days, and in those who were treated, it was a tadicious -
  • the index of therapeutic activity increased from a traditional order of 90% to a practical 100%, the rate was reduced and the treatment increased.
  • a further use of the GHS made it possible to increase the incidence of relapses of peptic ulcer disease.
  • the HSE conducted tests of how to accelerate drugs (food supplements) for people who lead active lifestyles with great mental and emotional burdens - businessmen, people who are doing business, For all, without exception, there was a marked improvement in overall well-being, an increase in business and general amenities.
  • drugs food supplements
  • HEPs were found to be effective in the event of ethical impairment, concomitant drugs, psychotropic drugs, analgesics, physical disruptions.
  • HES monohydrate 1-hydroxy-cigarette, digesto-methyl oxide
  • the HSS was used in conjunction with compounds that use non-toxic compounds (unified, Sa ⁇ a 2 ED ⁇ , penicillamine), see table 18.
  • HES monohydrate 1-hydroxy-cigarette, digesto-methyl oxide
  • HES monohydrate 1-hydroxy-cigarette, digesto-methyl oxide
  • GHS (monohydrate 1-hydroxy-cigarette, digesto-oxide,
  • ⁇ ' ⁇ 'Derived Simple and Comprehensive HHP Formula is a herbal cure for the treatment of herbal arthritis
  • Olzheymera ⁇ ⁇ 98/40103 ⁇ with pull9 / ⁇ 2b ⁇
  • ⁇ / ⁇ 2 ⁇ 2 is a dietary substance found in food
  • the product is equipped with a solid-state anti-gas / hydrogen generator and is equipped with a potent effi- ciency when nitrogen compounds (nitrate) are removed.
  • the product is a commercially available ⁇ / ⁇ HFC unit, the antidote is effective when it is controlled by an ethical system.
  • the efficiency of the unit is used, which is used without a Germanic unit. ⁇ ⁇ 98/40103 ⁇ 97 / 00261
  • ⁇ ak_t ⁇ _ ⁇ ⁇ . ⁇ gda ⁇ degta ⁇ it is the following: ⁇ réelle_. 55-81890 ⁇ ⁇ . (1980) // S. ⁇ .-1981.- ⁇ .94. - £ £ .84305e. 5 7. 5 and ⁇ k ⁇ G., ⁇ ⁇ . ⁇ .
  • Fig. 1 - The effect of a drug on a human body without the use of Germanic compounds.
  • 6- option 1 (AIDS prevention and recovery)
  • 7- option 2 long-term latent transfer of the virus to passive disease, that is, to the prevention of AIDS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à la médecine, plus particulièrement à la pharmacothérapie, et peut être utilisée pour renforcer l'effet thérapeutique et réduire la toxicité de médicaments, de métaux ainsi que de composés organiques ou inorganiques. Aux fins de l'invention, le patient doit absorber, conjointement aux substances susmentionnées, 1-hydroxygermatrane (germatranole, 1-hydroxy-1-germa-2, 8, 9-trioxa-5-azabicyclo 3.3.3 undécane) à raison de 0,001-0,1 gramme par jour et ses dérivés et/ou les dérivés de 1-germa-2, 8-dioxa-5-azacyclooctane. Par ailleurs, des médicaments peuvent se présenter sous la forme de substances biologiquement actives, contenues dans la nourriture, des milieux d'hygiène ou de cosmétologie ou des plantes, médicinales ou non. Les composés germano-organiques utilisés peuvent contenir un fragment de préparations médicales connues. Ce procédé permet d'accroître sensiblement l'activité pharmacologique de médicaments lors du traitement de diverses maladies et de réduire leur toxicité, notamment dans le cas de substances organiques ou inorganiques ou de métaux.
PCT/RU1997/000261 1997-03-11 1997-08-18 Procede visant a renforcer l'effet therapeutique et a reduire la toxicite de medicaments, de metaux ainsi que de composes organiques ou inorganiques WO1998040103A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39552/97A AU3955297A (en) 1997-03-11 1997-08-18 Process for increasing the therapeutic effect and reducing the toxicity of drugs, metals, and organic and inorganic compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU97103218 1997-03-11
RU97103219 1997-03-11
RU97103219A RU2104033C1 (ru) 1997-03-11 1997-03-11 Способ снижения токсичности лекарственных средств, металлов, органических и неорганических соединений и других токсинов
RU97103218A RU2104032C1 (ru) 1997-03-11 1997-03-11 Способ усиления лечебного эффекта лекарственных средств

Publications (1)

Publication Number Publication Date
WO1998040103A1 true WO1998040103A1 (fr) 1998-09-17

Family

ID=26653912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1997/000261 WO1998040103A1 (fr) 1997-03-11 1997-08-18 Procede visant a renforcer l'effet therapeutique et a reduire la toxicite de medicaments, de metaux ainsi que de composes organiques ou inorganiques

Country Status (2)

Country Link
AU (1) AU3955297A (fr)
WO (1) WO1998040103A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010561A1 (fr) * 1998-08-17 2000-03-02 Evgeny Vladimirovich Soloviev Complexes biochimiques de germanium a haute efficacite therapeutique et a large spectre d'application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2548187A1 (fr) * 1983-07-01 1985-01-04 Asai Germanium Res Inst Composes d'organo-germanium et leurs utilisations therapeutiques en tant qu'inhibiteurs des enzymes qui degradent les peptides opioides
FR2559488A1 (fr) * 1982-08-23 1985-08-16 Kakimoto Norihiro Composes d'organogermanium a la fois hydrophiles et lipophiles et procede pour leur production
US4654333A (en) * 1986-02-18 1987-03-31 Unimed, Inc. Treatment of multiple sclerosis
US4919917A (en) * 1987-10-29 1990-04-24 Asai Germanium Research Institute Co., Ltd. Agent for reducing nephrotoxicity caused by cyclosporin administration
EP0435693A2 (fr) * 1989-12-29 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. Compositions pharmaceutiques contenant des polymères de l'acide 3-oxygermylpropionique pour inhiber la dégénérescence cellulaire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2559488A1 (fr) * 1982-08-23 1985-08-16 Kakimoto Norihiro Composes d'organogermanium a la fois hydrophiles et lipophiles et procede pour leur production
FR2548187A1 (fr) * 1983-07-01 1985-01-04 Asai Germanium Res Inst Composes d'organo-germanium et leurs utilisations therapeutiques en tant qu'inhibiteurs des enzymes qui degradent les peptides opioides
US4654333A (en) * 1986-02-18 1987-03-31 Unimed, Inc. Treatment of multiple sclerosis
US4919917A (en) * 1987-10-29 1990-04-24 Asai Germanium Research Institute Co., Ltd. Agent for reducing nephrotoxicity caused by cyclosporin administration
EP0435693A2 (fr) * 1989-12-29 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. Compositions pharmaceutiques contenant des polymères de l'acide 3-oxygermylpropionique pour inhiber la dégénérescence cellulaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R.M. KHUSAINOV et al., "Novy Induktor Immunogo Interferona v Chelovecheskykh Leikotsitakh-Germanyorganischeskoe Soedinenie MOP-11", VOPROSY VIRUSOLOGII, 1991, No. 1, Volume 36, AKADEMYA MEDITSINSKIKH NAUK SSSR (Moscow), pages 63-64. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010561A1 (fr) * 1998-08-17 2000-03-02 Evgeny Vladimirovich Soloviev Complexes biochimiques de germanium a haute efficacite therapeutique et a large spectre d'application
US6451850B1 (en) 1998-08-17 2002-09-17 Evgeny Vladimirovich Soloviev Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum

Also Published As

Publication number Publication date
AU3955297A (en) 1998-09-29

Similar Documents

Publication Publication Date Title
US4514421A (en) Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
Stockings A new euphoriant for depressive mental states
WO1984002470A1 (fr) Preparation medicinale pour le traitement therapeutique d'ulceres peptiques
WO1994001099A1 (fr) Composition pharmaceutique presentant des actions anti-alcool stimulant le metabolisme de l'energie, stimulant les fonctions de production et de secretion d'acide de la membrane muqueuse de l'estomac, et presentant egalement des actions radioprotectrice et anti-cholera
RU2419449C1 (ru) Средство для лечения больных лекарственным гепатитом
WO2005102320A1 (fr) Medicament pour traiter des infections virales
WO1993013764A1 (fr) Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
WO1995017902A1 (fr) Utilisation d'une souche du champignon fusarium comme producteur de substances et preparation a base celle-ci presentant, des proprietes, adaptogeniques et immunomodulatrices
Brooke et al. Boric-acid poisoning: report of a case and review of the literature
Loeb Activity of a new antimalarial agent, pentaquine (Sn 13,276): Statement approved by the board for coordination of malarial studies
Kellogg Autointoxication; Or, Intestinal Toxemia
WO1994028153A2 (fr) Adn de faible masse moleculaire tiree de laitance d'esturgeon, procede d'obtention de l'adn et preparation pharmaceutique a base de celui-ci
WO1998040103A1 (fr) Procede visant a renforcer l'effet therapeutique et a reduire la toxicite de medicaments, de metaux ainsi que de composes organiques ou inorganiques
WO1995008318A2 (fr) Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse
WO1993000892A1 (fr) Preparation pharmaceutique
Green Oxygenation therapy unproven treatments for cancer and AIDS
WO1999016456A1 (fr) Preparation ayant une activite biologique, complexe de preparations et procede de stimulation immunologique
Wilson et al. An American text-book of applied therapeutics: for the use of practitioners and students
WO2005011648A2 (fr) Utilisation de bioisosteres cycliques de derives du systeme purique pour traiter des troubles provoques par la perturbation des systemes nitrergique et dopaminergique
Bodansky The effect of compounds related to hydrazine in producing anhydremia and experimental anemia
Pimparkar et al. A clinical trial of 1-dichloroacetyl-4-methylpiperidine (RD 7098) a new anti-amoebic drug
RU1808328C (ru) Способ лечени острых кишечных инфекционных заболеваний
JPS6261925A (ja) 脂質代謝促進剤
Stimson Nurses Handbook of Drugs and Solutions
Williams PROGRESS OF MEDICAL SCIENCE.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998539486

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA